Pipeline

Robust Pipeline with Multiple T-Cell Immunotherapy Product Candidates in Clinical Development

Tab-cel® (tabelecleucel)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
RR EBV+ PTLD following HCT

RR EBV+ PTLD following SOT

Nasopharyngeal carcinoma (NPC)

EBV+ cancers

Multiple Sclerosis (MS)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Autologous ATA190: Progressive MS

Off-the-shelf, allogeneic ATA188: Progressive MS

Next-Generation CAR T Pipeline
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA2271: Solid tumors

ATA2321: Acute myeloid leukemia

ATA2431: B-cell malignancies

ATA3219: Off-the-shelf, allogeneic B-cell malignancies

Autoimmune disease CAR T program

Infectious disease CAR T program

Other Programs
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA230: Refractory CMV Infection and Disease Post HCT/SOT

ATA520: Hematologic malignancies

ATA621: JCV PML and BKVAN

ATA368: HPV associated cancers